Ensysce Biosciences (ENSC) to Post Quarterly Earnings on Wednesday

Ensysce Biosciences (NASDAQ:ENSC) is anticipated to release its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect Ensysce Biosciences to announce earnings of ($0.50) per share and revenue of $1.90 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Ensysce Biosciences (NASDAQ:ENSC) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.21. Ensysce Biosciences had a negative return on equity of 766.45% and a negative net margin of 250.39%.The company had revenue of $0.96 million during the quarter, compared to the consensus estimate of $1.00 million. On average, analysts expect Ensysce Biosciences to post $-2 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Ensysce Biosciences Stock Down 15.7%

Shares of NASDAQ:ENSC opened at $0.32 on Wednesday. Ensysce Biosciences has a 52-week low of $0.23 and a 52-week high of $2.75. The stock’s fifty day simple moving average is $0.28 and its 200-day simple moving average is $0.43. The company has a market capitalization of $4.98 million, a P/E ratio of -0.10 and a beta of 0.84.

Hedge Funds Weigh In On Ensysce Biosciences

Hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC acquired a new stake in shares of Ensysce Biosciences during the 3rd quarter worth $34,000. Virtu Financial LLC purchased a new stake in Ensysce Biosciences during the 3rd quarter worth $34,000. DRW Securities LLC boosted its position in shares of Ensysce Biosciences by 42.4% in the fourth quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock worth $91,000 after buying an additional 29,336 shares during the period. Finally, Adage Capital Partners GP L.L.C. boosted its holdings in Ensysce Biosciences by 100.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock worth $138,000 after acquiring an additional 75,000 shares during the period. Institutional investors and hedge funds own 5.63% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ensysce Biosciences in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

About Ensysce Biosciences

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.